Financhill
Buy
76

GILD Quote, Financials, Valuation and Earnings

Last price:
$110.05
Seasonality move :
5.28%
Day range:
$107.43 - $110.11
52-week range:
$62.07 - $107.81
Dividend yield:
2.86%
P/E ratio:
290.95x
P/S ratio:
4.69x
P/B ratio:
6.97x
Volume:
6.1M
Avg. volume:
7.6M
1-year change:
50.39%
Market cap:
$134.2B
Revenue:
$28.8B
EPS (TTM):
$0.37

Analysts' Opinion

  • Consensus Rating
    Gilead Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of $107.03, Gilead Sciences has an estimated downside of -0.57% from its current price of $107.65.
  • Price Target Upside
    According to analysts, the highest upside price target is $126.00 representing 17.05% upside increase from its current price of $107.65.

Fair Value

  • According to the consensus of 26 analysts, Gilead Sciences has -0.57% downside to fair value with a price target of $107.03 per share.

GILD vs. S&P 500

  • Over the past 5 trading days, Gilead Sciences has overperformed the S&P 500 by 11.43% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Gilead Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Gilead Sciences has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Gilead Sciences reported revenues of $7.6B.

Earnings Growth

  • Gilead Sciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Gilead Sciences reported earnings per share of $1.42.
Enterprise value:
124.2B
EV / Invested capital:
6.45x
Price / LTM sales:
4.69x
EV / EBIT:
74.44x
EV / Revenue:
4.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.47x
Price / Operating cash flow:
12.45x
Enterprise value / EBITDA:
33.18x
Gross Profit (TTM):
$22.5B
Return On Assets:
0.84%
Net Income Margin (TTM):
1.67%
Return On Equity:
2.5%
Return On Invested Capital:
1.25%
Operating Margin:
32.25%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $27.3B $27.1B $28.8B $7.1B $7.6B
Gross Profit $21.6B $20.6B $22.5B $5B $6B
Operating Income $11B $8.8B $8.1B $2B $2.4B
EBITDA $8.9B $10.5B $3.7B $2.6B $2.4B
Diluted EPS $3.65 $4.50 $0.37 $1.14 $1.42
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $16B $14.8B $14.4B $16.1B $18B
Total Assets $68.4B $68B $63.2B $62.1B $59B
Current Liabilities $11.4B $11.6B $11.2B $11.3B $12B
Total Liabilities $50.2B $46.9B $42B $39.4B $39.7B
Total Equity $18.2B $21.1B $21.2B $22.7B $19.2B
Total Debt $31.4B $26.7B $25.2B $25B --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $9.1B $8B $10.8B $2.2B $3B
Cash From Investing -$2.5B -$2.3B -$3.4B -$727M -$225M
Cash From Financing -$6.5B -$5.1B -$3.4B -$1.1B $2.3B
Free Cash Flow $8.3B $7.4B $10.8B $2B $3.4B
GILD
Sector
Market Cap
$134.2B
$44.2M
Price % of 52-Week High
99.85%
48.19%
Dividend Yield
2.86%
0%
Shareholder Yield
7.68%
-0.68%
1-Year Price Total Return
50.39%
-35.43%
Beta (5-Year)
0.179
0.747
Dividend yield:
2.86%
Annualized payout:
$3.08
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $101.74
200-day SMA
Buy
Level $81.63
Bollinger Bands (100)
Buy
Level 0 - 0
Chaikin Money Flow
Sell
Level --
20-day SMA
Buy
Level $98.30
Relative Strength Index (RSI14)
Buy
Level 76.10
ADX Line
Neutral
Level 0
Williams %R
Sell
Level -1.2075
50-day SMA
Buy
Level $94.49
MACD (12, 26)
Buy
Level 3.25
25-day Aroon Oscillator
Buy
Level 96
On Balance Volume
Neutral
Level --

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8493)
Sell
CA Score (Annual)
Level (-0.8555)
Buy
Beneish M-Score (Annual)
Level (-2.7195)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.5364)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Stock Forecast FAQ

In the current month, GILD has received 15 Buy ratings 11 Hold ratings, and 0 Sell ratings. The GILD average analyst price target in the past 3 months is $107.03.

  • Where Will Gilead Sciences Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Gilead Sciences share price will drop to $107.03 per share over the next 12 months.

  • What Do Analysts Say About Gilead Sciences?

    Analysts are divided on their view about Gilead Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Gilead Sciences is a Sell and believe this share price will rise from its current level to $82.00.

  • What Is Gilead Sciences's Price Target?

    The price target for Gilead Sciences over the next 1-year time period is forecast to be $107.03 according to 26 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.

  • Is GILD A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Gilead Sciences is a Buy. 15 of 26 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of GILD?

    You can purchase shares of Gilead Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Gilead Sciences shares.

  • What Is The Gilead Sciences Share Price Today?

    Gilead Sciences was last trading at $110.05 per share. This represents the most recent stock quote for Gilead Sciences. Yesterday, Gilead Sciences closed at $107.65 per share.

  • How To Buy Gilead Sciences Stock Online?

    In order to purchase Gilead Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
17
CE alert for Feb 21

Celanese [CE] is down 4.21% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 8.41% over the past day.

Buy
72
HIMS alert for Feb 20

Hims & Hers Health [HIMS] is down 3.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock